191 related articles for article (PubMed ID: 18181199)
1. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
Tefferi A; Kantarjian H
Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
[No Abstract] [Full Text] [Related]
2. Chronic myelogenous leukemia therapy beyond imatinib.
Deininger M
Clin Adv Hematol Oncol; 2010 Mar; 8(3):178-80. PubMed ID: 20400933
[No Abstract] [Full Text] [Related]
3. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
4. [Imatinib].
Urabe A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
[TBL] [Abstract][Full Text] [Related]
5. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
6. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
7. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
8. Diabetes research. Researchers puzzle over possible effect of Gleevec.
Couzin J
Science; 2005 Mar; 307(5716):1711. PubMed ID: 15774738
[No Abstract] [Full Text] [Related]
9. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
[No Abstract] [Full Text] [Related]
10. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Hwang YY; Tse E; So JC; Wan TS; Kwong YL
Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
[No Abstract] [Full Text] [Related]
11. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
12. Imatinib and regression of type 2 diabetes.
Veneri D; Franchini M; Bonora E
N Engl J Med; 2005 Mar; 352(10):1049-50. PubMed ID: 15758023
[No Abstract] [Full Text] [Related]
13. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
14. Imatinib mesylate--a new oral targeted therapy.
Savage DG; Antman KH
N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
[No Abstract] [Full Text] [Related]
15. Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.
Breccia M; De Cuia MR; D'Elia GM; Francesca B; Mandelli F; Alimena G
Haematologica; 2004 Jul; 89(7):ECR20. PubMed ID: 15257957
[No Abstract] [Full Text] [Related]
16. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
17. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
18. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Rodrigues MS; Sattler M
J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
[No Abstract] [Full Text] [Related]
19. An 85-year-old Japanese woman with Philadelphia chromosome-positive chronic myelogenous leukemia with del (5q) successfully treated by intermittent imatinib therapy.
Maeda T; Mutoh T; Muta H; Nakayama M; Nakajima Y; Ikuta T; Yasuda M; Etoh T; Shimizu K; Nakazaki Y; Hiroyama T; Somada S; Kurita R; Tani K; Shiratsuchi M; Nishimura J
J Am Geriatr Soc; 2004 Oct; 52(10):1783-4. PubMed ID: 15450069
[No Abstract] [Full Text] [Related]
20. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
